Pediatrix Medical Group, Inc. Logo

Pediatrix Medical Group, Inc.

MD

(1.8)
Stock Price

14,09 USD

-31.23% ROA

-32.29% ROE

-4.23x PER

Market Cap.

1.015.792.414,00 USD

91.89% DER

0% Yield

-12.65% NPM

Pediatrix Medical Group, Inc. Stock Analysis

Pediatrix Medical Group, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Pediatrix Medical Group, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 PBV

The stock's low PBV ratio (0.78x) suggests it's undervalued, making it an attractive opportunity for investors.

3 ROE

ROE in an average range (12.11%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 DER

The stock has a reasonable amount of debt compared to its ownership (73%), suggesting a balanced financial position and a moderate level of risk.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-448) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Pediatrix Medical Group, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Pediatrix Medical Group, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Pediatrix Medical Group, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Pediatrix Medical Group, Inc. Revenue
Year Revenue Growth
1994 32.800.000
1995 43.900.000 25.28%
1996 80.800.000 45.67%
1997 128.900.000 37.32%
1998 185.400.000 30.47%
1999 227.000.000 18.33%
2000 243.075.000 6.61%
2001 354.595.000 31.45%
2002 465.481.000 23.82%
2003 551.197.000 15.55%
2004 619.629.000 11.04%
2005 693.700.000 10.68%
2006 818.554.000 15.25%
2007 917.644.000 10.8%
2008 1.068.277.000 14.1%
2009 1.288.264.000 17.08%
2010 1.401.559.000 8.08%
2011 1.588.248.000 11.75%
2012 1.816.612.000 12.57%
2013 2.154.012.000 15.66%
2014 2.438.913.000 11.68%
2015 2.779.996.000 12.27%
2016 3.183.159.000 12.67%
2017 3.458.312.000 7.96%
2018 3.647.123.000 5.18%
2019 3.513.542.000 -3.8%
2020 1.733.951.000 -102.63%
2021 1.911.191.000 9.27%
2022 1.972.021.000 3.08%
2023 2.026.448.000 2.69%
2023 1.994.640.000 -1.59%
2024 2.017.184.000 1.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Pediatrix Medical Group, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Pediatrix Medical Group, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 0
1995 0 0%
1996 52.700.000 100%
1997 81.500.000 35.34%
1998 113.700.000 28.32%
1999 148.900.000 23.64%
2000 177.718.000 16.22%
2001 274.719.000 35.31%
2002 0 0%
2003 76.537.000 100%
2004 79.445.000 3.66%
2005 115.304.000 31.1%
2006 109.057.000 -5.73%
2007 119.766.000 8.94%
2008 124.965.000 4.16%
2009 124.965.000 0%
2010 154.267.000 18.99%
2011 170.356.000 9.44%
2012 193.540.000 11.98%
2013 218.209.000 11.31%
2014 247.527.000 11.84%
2015 305.915.000 19.09%
2016 372.572.000 17.89%
2017 417.105.000 10.68%
2018 432.378.000 3.53%
2019 404.643.000 -6.85%
2020 248.947.000 -62.54%
2021 263.357.000 5.47%
2022 231.397.000 -13.81%
2023 229.624.000 -0.77%
2023 227.542.000 -0.91%
2024 226.260.000 -0.57%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Pediatrix Medical Group, Inc. EBITDA
Year EBITDA Growth
1994 9.100.000
1995 10.100.000 9.9%
1996 19.800.000 48.99%
1997 35.500.000 44.23%
1998 57.000.000 37.72%
1999 56.700.000 -0.53%
2000 38.324.000 -47.95%
2001 79.878.000 52.02%
2002 117.392.000 31.96%
2003 144.812.000 18.93%
2004 164.683.000 12.07%
2005 156.404.000 -5.29%
2006 204.108.000 23.37%
2007 224.608.000 9.13%
2008 255.100.000 11.95%
2009 305.377.000 16.46%
2010 334.861.000 8.8%
2011 380.681.000 12.04%
2012 420.336.000 9.43%
2013 492.097.000 14.58%
2014 560.769.000 12.25%
2015 625.223.000 10.31%
2016 664.136.000 5.86%
2017 583.907.000 -13.74%
2018 563.954.000 -3.54%
2019 495.134.000 -13.9%
2020 201.959.000 -145.17%
2021 251.797.000 19.79%
2022 237.358.000 -6.08%
2023 118.676.000 -100.01%
2023 196.080.000 39.48%
2024 230.216.000 14.83%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Pediatrix Medical Group, Inc. Gross Profit
Year Gross Profit Growth
1994 30.000.000
1995 40.400.000 25.74%
1996 74.500.000 45.77%
1997 119.100.000 37.45%
1998 171.300.000 30.47%
1999 205.900.000 16.8%
2000 216.400.000 4.85%
2001 354.595.000 38.97%
2002 449.690.000 21.15%
2003 532.609.000 15.57%
2004 595.375.000 10.54%
2005 666.022.000 10.61%
2006 317.001.000 -110.1%
2007 350.260.000 9.5%
2008 380.065.000 7.84%
2009 452.539.000 16.01%
2010 489.128.000 7.48%
2011 551.037.000 11.23%
2012 613.876.000 10.24%
2013 710.306.000 13.58%
2014 806.516.000 11.93%
2015 928.011.000 13.09%
2016 1.033.523.000 10.21%
2017 1.000.060.000 -3.35%
2018 989.507.000 -1.07%
2019 891.998.000 -10.93%
2020 449.321.000 -98.52%
2021 513.242.000 12.45%
2022 467.033.000 -9.89%
2023 427.556.000 -9.23%
2023 421.565.000 -1.42%
2024 421.312.000 -0.06%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Pediatrix Medical Group, Inc. Net Profit
Year Net Profit Growth
1994 5.400.000
1995 6.700.000 19.4%
1996 13.100.000 48.85%
1997 20.900.000 37.32%
1998 29.100.000 28.18%
1999 25.000.000 -16.4%
2000 10.986.000 -127.56%
2001 30.428.000 63.9%
2002 68.776.000 55.76%
2003 84.328.000 18.44%
2004 98.279.000 14.2%
2005 89.037.000 -10.38%
2006 124.465.000 28.46%
2007 142.722.000 12.79%
2008 169.201.000 15.65%
2009 175.804.000 3.76%
2010 202.691.000 13.27%
2011 217.997.000 7.02%
2012 240.907.000 9.51%
2013 280.517.000 14.12%
2014 317.281.000 11.59%
2015 336.320.000 5.66%
2016 324.914.000 -3.51%
2017 320.372.000 -1.42%
2018 268.629.000 -19.26%
2019 -1.150.094.000 123.36%
2020 -9.580.000 -11905.16%
2021 130.964.000 107.31%
2022 66.335.000 -97.43%
2023 161.092.000 58.82%
2023 -60.408.000 366.67%
2024 -612.100.000 90.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Pediatrix Medical Group, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 0 0%
2006 1 100%
2007 1 0%
2008 2 0%
2009 2 0%
2010 2 50%
2011 2 0%
2012 2 0%
2013 3 0%
2014 3 33.33%
2015 4 0%
2016 3 0%
2017 3 0%
2018 3 -50%
2019 -14 115.38%
2020 0 0%
2021 2 100%
2022 1 0%
2023 2 100%
2023 -1 0%
2024 -7 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Pediatrix Medical Group, Inc. Free Cashflow
Year Free Cashflow Growth
1994 4.800.000
1995 4.000.000 -20%
1996 10.100.000 60.4%
1997 -33.400.000 130.24%
1998 -58.400.000 42.81%
1999 -31.000.000 -88.39%
2000 22.770.000 236.14%
2001 59.514.000 61.74%
2002 89.849.000 33.76%
2003 102.760.000 12.56%
2004 116.696.000 11.94%
2005 154.533.000 24.48%
2006 164.398.000 6%
2007 180.013.000 8.67%
2008 165.711.000 -8.63%
2009 226.427.000 26.81%
2010 228.445.000 0.88%
2011 239.687.000 4.69%
2012 311.197.000 22.98%
2013 389.744.000 20.15%
2014 404.580.000 3.67%
2015 341.628.000 -18.43%
2016 404.514.000 15.55%
2017 462.069.000 12.46%
2018 241.057.000 -91.68%
2019 314.756.000 23.41%
2020 175.832.000 -79.01%
2021 44.488.000 -295.23%
2022 137.233.000 67.58%
2023 70.784.000 -93.88%
2023 103.997.000 31.94%
2024 99.989.000 -4.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Pediatrix Medical Group, Inc. Operating Cashflow
Year Operating Cashflow Growth
1994 5.400.000
1995 5.900.000 8.47%
1996 14.800.000 60.14%
1997 29.000.000 48.97%
1998 33.800.000 14.2%
1999 24.000.000 -40.83%
2000 36.149.000 33.61%
2001 90.336.000 59.98%
2002 97.842.000 7.67%
2003 118.034.000 17.11%
2004 123.753.000 4.62%
2005 162.418.000 23.81%
2006 177.272.000 8.38%
2007 188.522.000 5.97%
2008 181.391.000 -3.93%
2009 241.374.000 24.85%
2010 240.558.000 -0.34%
2011 271.019.000 11.24%
2012 325.692.000 16.79%
2013 405.398.000 19.66%
2014 422.641.000 4.08%
2015 368.701.000 -14.63%
2016 443.778.000 16.92%
2017 511.378.000 13.22%
2018 289.925.000 -76.38%
2019 346.637.000 16.36%
2020 204.620.000 -69.41%
2021 76.737.000 -166.65%
2022 166.941.000 54.03%
2023 79.938.000 -108.84%
2023 137.325.000 41.79%
2024 106.951.000 -28.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Pediatrix Medical Group, Inc. Capital Expenditure
Year Capital Expenditure Growth
1994 600.000
1995 1.900.000 68.42%
1996 4.700.000 59.57%
1997 62.400.000 92.47%
1998 92.200.000 32.32%
1999 55.000.000 -67.64%
2000 13.379.000 -311.09%
2001 30.822.000 56.59%
2002 7.993.000 -285.61%
2003 15.274.000 47.67%
2004 7.057.000 -116.44%
2005 7.885.000 10.5%
2006 12.874.000 38.75%
2007 8.509.000 -51.3%
2008 15.680.000 45.73%
2009 14.947.000 -4.9%
2010 12.113.000 -23.4%
2011 31.332.000 61.34%
2012 14.495.000 -116.16%
2013 15.654.000 7.4%
2014 18.061.000 13.33%
2015 27.073.000 33.29%
2016 39.264.000 31.05%
2017 49.309.000 20.37%
2018 48.868.000 -0.9%
2019 31.881.000 -53.28%
2020 28.788.000 -10.74%
2021 32.249.000 10.73%
2022 29.708.000 -8.55%
2023 9.154.000 -224.54%
2023 33.328.000 72.53%
2024 6.962.000 -378.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Pediatrix Medical Group, Inc. Equity
Year Equity Growth
1994 16.100.000
1995 62.800.000 74.36%
1996 136.300.000 53.93%
1997 163.700.000 16.74%
1998 207.400.000 21.07%
1999 228.900.000 9.39%
2000 241.900.000 5.37%
2001 478.852.000 49.48%
2002 547.998.000 12.62%
2003 572.378.000 4.26%
2004 571.031.000 -0.24%
2005 691.791.000 17.46%
2006 865.801.000 20.1%
2007 959.052.000 9.72%
2008 965.138.000 0.63%
2009 1.190.098.000 18.9%
2010 1.447.454.000 17.78%
2011 1.731.016.000 16.38%
2012 2.035.368.000 14.95%
2013 2.342.988.000 13.13%
2014 2.266.513.000 -3.37%
2015 2.438.164.000 7.04%
2016 2.760.767.000 11.69%
2017 3.066.454.000 9.97%
2018 3.087.884.000 0.69%
2019 1.498.996.000 -106%
2020 747.949.000 -100.41%
2021 896.897.000 16.61%
2022 891.632.000 -0.59%
2023 967.985.000 7.89%
2023 849.061.000 -14.01%
2024 706.461.000 -20.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Pediatrix Medical Group, Inc. Assets
Year Assets Growth
1994 20.300.000
1995 69.900.000 70.96%
1996 159.000.000 56.04%
1997 196.800.000 19.21%
1998 270.700.000 27.3%
1999 334.800.000 19.15%
2000 324.734.000 -3.1%
2001 573.099.000 43.34%
2002 648.679.000 11.65%
2003 717.594.000 9.6%
2004 788.889.000 9.04%
2005 900.403.000 12.38%
2006 1.135.170.000 20.68%
2007 1.302.802.000 12.87%
2008 1.496.874.000 12.97%
2009 1.689.350.000 11.39%
2010 2.037.646.000 17.09%
2011 2.272.648.000 10.34%
2012 2.750.337.000 17.37%
2013 3.049.430.000 9.81%
2014 3.608.795.000 15.5%
2015 4.547.214.000 20.64%
2016 5.339.400.000 14.84%
2017 5.867.278.000 9%
2018 5.934.911.000 1.14%
2019 4.145.901.000 -43.15%
2020 3.347.948.000 -23.83%
2021 2.722.546.000 -22.97%
2022 2.347.887.000 -15.96%
2023 2.326.339.000 -0.93%
2023 2.219.810.000 -4.8%
2024 1.995.351.000 -11.25%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Pediatrix Medical Group, Inc. Liabilities
Year Liabilities Growth
1994 4.200.000
1995 7.100.000 40.85%
1996 22.700.000 68.72%
1997 33.100.000 31.42%
1998 63.300.000 47.71%
1999 105.900.000 40.23%
2000 82.834.000 -27.85%
2001 94.247.000 12.11%
2002 100.681.000 6.39%
2003 145.216.000 30.67%
2004 217.858.000 33.34%
2005 208.612.000 -4.43%
2006 269.369.000 22.56%
2007 343.750.000 21.64%
2008 531.736.000 35.35%
2009 499.252.000 -6.51%
2010 590.192.000 15.41%
2011 541.632.000 -8.97%
2012 714.969.000 24.24%
2013 706.442.000 -1.21%
2014 1.343.229.000 47.41%
2015 2.109.368.000 36.32%
2016 2.578.633.000 18.2%
2017 2.800.824.000 7.93%
2018 2.847.027.000 1.62%
2019 2.646.905.000 -7.56%
2020 2.600.231.000 -1.79%
2021 1.825.854.000 -42.41%
2022 1.456.255.000 -25.38%
2023 1.358.354.000 -7.21%
2023 1.370.749.000 0.9%
2024 1.288.890.000 -6.35%

Pediatrix Medical Group, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
24.03
Net Income per Share
-2.8
Price to Earning Ratio
-4.23x
Price To Sales Ratio
0.51x
POCF Ratio
7.53
PFCF Ratio
10.12
Price to Book Ratio
1.4
EV to Sales
0.85
EV Over EBITDA
9.94
EV to Operating CashFlow
12.95
EV to FreeCashFlow
16.88
Earnings Yield
-0.24
FreeCashFlow Yield
0.1
Market Cap
1,02 Bil.
Enterprise Value
1,69 Bil.
Graham Number
23.09
Graham NetNet
-11.4

Income Statement Metrics

Net Income per Share
-2.8
Income Quality
-0.52
ROE
-0.28
Return On Assets
-0.12
Return On Capital Employed
-0
Net Income per EBT
0.93
EBT Per Ebit
60.41
Ebit per Revenue
-0
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.2
Operating Profit Margin
-0
Pretax Profit Margin
-0.14
Net Profit Margin
-0.13

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.57
Free CashFlow per Share
1.21
Capex to Operating CashFlow
0.23
Capex to Revenue
0.02
Capex to Depreciation
0.82
Return on Invested Capital
0
Return on Tangible Assets
-0.31
Days Sales Outstanding
49.97
Days Payables Outstanding
7.28
Days of Inventory on Hand
0
Receivables Turnover
7.3
Payables Turnover
50.14
Inventory Turnover
0
Capex per Share
0.37

Balance Sheet

Cash per Share
1,60
Book Value per Share
8,48
Tangible Book Value per Share
-6.51
Shareholders Equity per Share
8.48
Interest Debt per Share
8.04
Debt to Equity
0.92
Debt to Assets
0.33
Net Debt to EBITDA
3.98
Current Ratio
1.38
Tangible Asset Value
-0,54 Bil.
Net Current Asset Value
-0,86 Bil.
Invested Capital
1481541000
Working Capital
0,12 Bil.
Intangibles to Total Assets
0.63
Average Receivables
0,28 Bil.
Average Payables
0,12 Bil.
Average Inventory
0.5
Debt to Market Cap
0.64

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Pediatrix Medical Group, Inc. Dividends
Year Dividends Growth

Pediatrix Medical Group, Inc. Profile

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

CEO
Dr. James D. Swift M.D.
Employee
5.450
Address
1301 Concord Terrace
Sunrise, 33323

Pediatrix Medical Group, Inc. Executives & BODs

Pediatrix Medical Group, Inc. Executives & BODs
# Name Age
1 Mr. Daniel Patrick Corcoran
Senior Vice President of Administration & Managed Care
70
2 Dr. James D. Swift M.D.
Chief Executive Officer & Director
70
3 Ms. Debra McRoberts
Senior Vice President of People Services
70
4 Mr. John C. Pepia
Senior Vice President & Chief Accounting Officer
70
5 Mr. Mike Ashford
President of Regional Operations (Central)
70
6 Ms. Mary Ann E. Moore J.D.
Chief Administrative Officer, Executive Vice President, General Counsel & Secretary
70
7 Ms. Kasandra H. Rossi
Executive Vice President, Treasurer & Chief Financial Officer
70
8 Mr. Charles W. Lynch C.F.A.
Senior Vice President of Finance, Strategy & Investor Relations
70
9 Dr. Michael Dwyer M.D.
President of Regional Operations (South-Central)
70
10 Ms. Cheryl M. VanPatten
Senior Vice President & Chief Information Officer
70

Pediatrix Medical Group, Inc. Competitors